HemoBioTech Gains Congressional Recognition of Its Blood Substitute Technology

DALLAS, TX--(Marketwire - August 17, 2009) - HemoBioTech, Inc. (OTCBB: HMBT) has been working
with a coalition of small biotechnology firms to implement legislation that
will strengthen the Federal government's stewardship role in the protection
and preservation of pre-revenue biotechnology companies.

In addition, the HemoBioTech's blood substitute technology recently gained
support from the office of Rep. Edolphus Towns of New York, whose office
circulated a letter to House Members addressing the urgent need for a blood
substitute to prevent HIV AIDS from HIV contaminated blood, especially in
the world's poorest nations. Cited in the letter is the use of hemoglobin
modified with adenosine as a viable blood substitute. Adenosine modified
hemoglobin is a fundamental feature of HemoTech which is being developed by
HemoBioTech as the first viable blood substitute and is patented in 21
countries. Congressman Towns also supports an investment of $35 million and
a proposal to work with the FDA to fast tract the development of the
technology. The full letter follows this release.

"Congressional recognition is critical as HemoBioTech advances through the
development of HemoTech, its adenosine modified hemoglobin blood
substitute," said HemoBioTech's Chairman and CEO, Arthur P. Bollon, Ph.D.
"We look forward to working with Congressman Towns and other members of
Congress in implementing these proposals."

About HemoBioTech, Inc.

HemoBioTech is engaged in the commercial development of HemoTech, a novel
human blood substitute technology developed by Texas Tech University Health
Sciences Center scientists, Drs. Mario Feola and Jan Simoni. HemoTech is
exclusively licensed by HemoBioTech from Texas Tech University System.
HemoTech is composed of bovine hemoglobin that is chemically modified with
ATP, Adenosine and GSH.

Researchers believe that HemoTech carries oxygen in the blood, and induces
erythropoiesis (red blood cell production). The Company believes that
HemoTech, due to its novel chemical structure, may possess properties that
diminish the intrinsic toxicities that have plagued other attempts at
developing blood substitutes, based upon pre-clinical and initial human
clinical trials undertaken outside the U.S.

HemoTech is being subjected to further studies and testing to confirm and
possibly expand on these initial results. HemoTech is being developed to
help reduce or eliminate the danger resulting from acute blood loss in
trauma, anemia, as well as for other conditions. HemoTech is an
investigational biological drug that has not been approved by the U.S. Food
and Drug Administration and cannot currently be marketed. Corporate
headquarters are located at 5001 Spring Valley Road, Suite 1040-West,
Dallas, Texas 75244.

Safe Harbor Statement

Except for historical information, the matters discussed in this news
release may be considered "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of
HemoBioTech and its management and are valid only as of today, and we
disclaim any obligation to update this information. These statements are
subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements
made. Factors that might cause such a difference include, among others the
successful pre-clinical development, the successful completion of clinical
trials, the FDA review process and other governmental regulation,
pharmaceutical collaborator interest and ability to successfully develop
and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third party reimbursement, and other factors
which are included in HemoBioTech's Annual Report on Form 10-K for the year
ending December 31, 2007, as amended, and HemoBioTech's other reports filed
with the Securities and Exchange Commission.